Re-analysis of data on use of breast cancer medicine Lapatinib following treatment with trastuzumab

April 30, 2019 – EMA is updating the prescribing information for lapatinib following detection of errors in results of a study involving postmenopausal women who had ‘HR+/HER2+’ breast cancer and whose disease had worsened despite previous treatment with trastuzumab. The results had indicated a benefit of Tyverb over trastuzumab when each medicine was used together with an aromatase inhibitor. The detected errors were included in the prescribing … (leggi tutto)